Cambridge Antibody Technology Group Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jongmans who started this subject	6/12/2002 6:20:30 PM
From: nigel bates	of 625

Biosite's Dower Patent Upheld In Europe SAN DIEGO -(Dow Jones)- Biosite Inc. said the European Patent Office upheld its European Dower patents, dismissing arguments from Cambridge Antibody Technology Group and others undisclosed firms. In a press release Wednesday, diagnostic product maker Biosite said it now plans to pursue licensing opportunities related to the patents. The Dower patents, which were acquired from Affymax Technologies N.V. in 1998, cover a technology that isolates antibodies for diagnosis, spokeswoman Nadine Padilla said. Cambridge Antibody and other firms alleged Biosite's patents were invalid on various grounds, Padilla added. She wouldn't elaborate on the allegations, but said they only pertained to the European version of the Dower patents. The San Diego company is still involved in a separate lawsuit with Xoma Ltd. ( XOMA), regarding patents covering Biosite's antibody expression technology. Biosite licensed an antibody technology from Xoma and has been using the product to test antibodies for pharmaceutical companies in drug development. Xoma alleges the use of its technology for this purpose is outside of the companies' original agreement...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next